Tolvaptan



Tolvaptan
Systematic (IUPAC) name
N-{4-[(6R)-9-chloro-6-hydroxy-2-azabicyclo[5.4.0]
undeca-8,10,12-triene-2-carbonyl]-3-methyl-phenyl}-
2-methyl-benzamide
Identifiers
CAS number 150683-30-0
ATC code  ?
PubChem 443894
Chemical data
O3 
Mol. mass 448.941 g/mol
Pharmacokinetic data
Bioavailability  ?
CYP3A4-mediated)[1]
Half life 6 to 8 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Oral

Tolvaptan (polycystic kidney disease.

In a 2004 trial, tolvaptan, when administered with traditional hypokalemia (decreased blood levels of potassium) and without having an adverse effect on kidney function.[2]

Notes

  1. ^ Shoaf S, Elizari M, Wang Z et al. (2005). "Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias". J Cardiovasc Pharmacol Ther 10 (3): 165-71. PMID 16211205.
  2. ^ Gheorghiade M, Gattis W, O'Connor C et al. (2004). "Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial". JAMA 291 (16): 1963-71. PMID 15113814.

References

  • Gheorghiade M, Niazi I, Ouyang J et al. (2003). "Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial". Circulation 107 (21): 2690-6. PMID 12742979.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tolvaptan". A list of authors is available in Wikipedia.